Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4436-4455
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4436
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4436
BIRClow group (n = 23) | BIRChigh group (n = 37) | P value | |
Sex (male) | 19 (82.6) | 24 (81.1) | 0.2701 |
Age (year) | 65.43 ± 10.77 | 64.97 ± 7.58 | 0.1102 |
BMI (kg/m2) | 23.46 ± 3.43 | 24.84 ± 3.77 | 0.8922 |
HER2 | 0.047 | ||
HER2 (-) | 16 (69.6) | 16 (43.2) | |
HER2 (+) | 7 (30.4) | 21 (56.8) | |
Tumor size (cm) | 3.43 ± 2.02 | 4.59 ± 1.84 | 0.5002 |
Differentiation | 0.489 | ||
Poor | 9 (39.1) | 24 (64.9) | |
Moderate | 14 (60.9) | 10 (27.0) | |
High | 0 (0.0) | 3 (8.1) | |
T stage | 0.001 | ||
1 | 5 (13.5) | 1 (2.7) | |
2 | 7 (18.9) | 6 (16.2) | |
3 | 10 (27.0) | 11 (29.7) | |
4 | 1 (2.7) | 19 (51.4) | |
N stage | 0.208 | ||
0 | 11 (29.7) | 8 (21.6) | |
1 | 10 (27.0) | 20 (54.1) | |
2 | 2 (5.4) | 5 (13.5) | |
3 | 0 (0.0) | 4 (10.8) | |
M stage | 0.691 | ||
0 | 23 (100.0) | 35 (94.6) | |
1 | 0 (0.0) | 2 (5.4) | |
TNM stage | 0.007 | ||
I | 4 (10.8) | 1 (2.7) | |
II | 5 (13.5) | 1 (2.7) | |
III | 12 (32.4) | 24 (64.9) | |
IV | 2 (5.4) | 11 (29.7) | |
OS (month) | |||
mean ± SD | 32.2 ± 16.33 | 21.81 ± 15.17 | 0.0152 |
Median (range) | 33 (3-53) | 15 (5-53) | - |
DFS (month) | |||
mean ± SD | 26.74 ± 14.80 | 18.57 ± 14.21 | 0.0402 |
Median (range) | 26 (3-52) | 15 (2-53) | - |
- Citation: Li SL, Wang PY, Jia YP, Zhang ZX, He HY, Chen PY, Liu X, Liu B, Lu L, Fu WH. BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer. World J Gastrointest Oncol 2024; 16(11): 4436-4455
- URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4436.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4436